23andMe Holding Co. (Nasdaq: ME), a leading human genetics and
preventive health company, reported its financial results for the
second quarter of fiscal year 2025 (FY25), which ended September
30, 2024.
Key Results:
- Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for
the same period in the prior year (see important additional
information below).
- The 23andMe comprehensive Total Health longevity service is now
available to all customers, combining whole exome genetic
sequencing with bi-annual lab tests for 55+ key blood biomarkers,
and expert clinicians trained in genetics-informed preventive care
and health action plans.
- Launched a GLP-1 weight loss telehealth membership on the
Lemonaid Health platform that enables members to be prescribed and
receive brand name or compounded semaglutide medications. Also
launched and enrolled thousands of participants in a new study to
understand how genetics can impact GLP-1 efficacy, side effects,
and length of treatment.
- Launched a new genetic report on Emotional Eating, utilizing
23andMe’s polygenic risk score technology, for 23andMe+ Premium
subscribers.
- Launched the first AI chatbot available to 23andMe customers,
“DaNA,” to highlight key health and other important results for
customers, making actionable insights easier to identify.
- Presented a new study demonstrating that using 23andMe Research
data not only supports previous research that shows that targets
supported by human genetics are 2 to 3 times more likely to
succeed, but also uncovers many novel insights and can increase the
relative rate of success even further.
- Published one of the largest and most diverse genetic studies
of sickle cell trait, in collaboration with the National Institutes
of Health and Johns Hopkins University School of Medicine.
- Together with more than 20 lung cancer advocacy groups,
launched a large-scale lung cancer study to investigate the
genetics of the disease, aiming to enroll 10,000 patients; the
effort has already enrolled more than 1,000 patients making it the
largest study of its kind.
Recent Developments:
- Reconstituted Board of Directors with the appointments of Andre
Fernandez, Jim Frankola, and Mark Jensen.
- Regained compliance with Nasdaq listing requirements following
Board appointments and completion of 1-for-20 reverse stock
split.
- Commenced business restructuring to streamline operations,
reduce costs and position the business for the future.
“We are making significant progress to ensure the long-term
success of the business as we continue on our mission,” said Anne
Wojcicki, CEO and Co-Founder of 23andMe. “We have been focused on
growing our subscription business by adding more value and driving
greater engagement, and as a result we’ve more than doubled our
membership services revenue from the prior year quarter. We will
continue to prioritize driving recurring revenue through our
subscription business, in addition to growing our research
partnership business as we look to the future.”
Q2 Fiscal 2025 Financial ResultsTotal revenue
for FY25 Q2 was $44 million, compared to $50 million for the same
period in the prior year, representing a decrease of 12%. The
decrease was primarily driven by lower consumer services revenue
driven mainly by lower PGS kit sales volume and telehealth orders,
as well as lower research services revenue as the GSK collaboration
exclusive discovery term concluded in July 2023. These decreases
were partially offset by growth in membership services revenue,
which represented 21% of total revenue versus 9% in the prior year
quarter, as the Company continues focusing on higher margin
recurring revenue streams.
Operating expenses for FY25 Q2 were $84 million, compared to
$101 million for the same period in the prior year, a 17% decrease.
The decrease in operating expenses for the quarter was driven by
lower personnel-related expenses, including non-cash stock-based
compensation expenses, following workforce reductions in the
current and prior quarters, and the disposition of Lemonaid Health
Limited in the UK in August 2023. The improvement also reflects
lower Therapeutics-related R&D spend as we opted for a royalty
on several GSK partnered programs, resulting in a significant
reduction of GSK collaboration expenses compared to the prior year
quarter.
GAAP Net loss for FY25 Q2 was $59 million, a 21% improvement
compared to a net loss of $75 million for the same period in the
prior year.
Adjusted EBITDA (as defined below) for FY25 Q2 was a loss of $33
million, a 26% improvement compared to a loss of $45 million for
the same period in the prior year. The improvement in adjusted
EBITDA was primarily due to lower R&D and personnel-related
expenses, and improvements in consumer services gross profit,
partially offset by lower research services gross profit. Please
refer to the tables below for a reconciliation of U.S. GAAP to
Non-U.S. GAAP financial measures.
Balance Sheet 23andMe ended September 30, 2024
with cash and cash equivalents of $127 million, compared to $216
million as of March 31, 2024. 23andMe has no debt on its balance
sheet.
As announced yesterday, the Company is restructuring the
business by streamlining operations, reducing costs and positioning
the Company for long-term success in the future. In addition, the
Company is exploring raising additional capital and continuing to
grow the research partnership business. These efforts will improve
its financial condition and liquidity position to extend our cash
runway.
Conference Call Webcast Information23andMe will
host a conference call at 8:00 a.m. Eastern Time today, November
12, 2024, to discuss the financial results for Q2 FY2025 and report
on business progress. The webcast can be accessed at
https://investors.23andme.com/news-events/events-presentations. A
webcast replay will be available at the same address.
About 23andMe23andMe is a genetics-led consumer
healthcare company empowering a healthier future. For more
information, please visit investors.23andme.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, financial projections,
funding for continued operations, cash reserves, projected costs,
database growth, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," “predicts,”
"continue," "will," “schedule,” and "would" or, in each case, their
negative or other variations or comparable terminology, are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on 23andMe’s
current expectations and projections about future events and
various assumptions. 23andMe cannot guarantee that it will actually
achieve the plans, intentions, or expectations disclosed in its
forward-looking statements and you should not place undue reliance
on 23andMe’s forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (many of which
are beyond the control of 23andMe), or other assumptions that may
cause actual results or performance to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, as filed with the
Securities and Exchange Commission, and as revised and updated by
our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Use of Non-GAAP Financial MeasuresTo supplement
the 23andMe’s unaudited condensed consolidated statements of
operations and unaudited condensed consolidated balance sheets,
which are prepared in conformity with generally accepted accounting
principles in the United States of America (GAAP), this press
release also includes references to Adjusted EBITDA, a non-GAAP
financial measure that is defined as net income (loss) before net
interest income (expense), net other income (expense), income tax
expenses (benefit), depreciation and amortization, impairment
charges, stock-based compensation expense, and other items that are
considered unusual or not representative of underlying trends of
our business, including but not limited to: litigation settlements,
gains or losses on dispositions of subsidiaries,
transaction-related costs, and cyber security incident expenses,
net of probable insurance recoveries, if applicable for the periods
presented. 23andMe has provided a reconciliation of net loss, the
most directly comparable GAAP financial measure, to Adjusted EBITDA
at the end of this press release.
Adjusted EBITDA is a key measure used by 23andMe’s management
and the board of directors to understand and evaluate operating
performance and trends, to prepare and approve 23andMe’s annual
budget and to develop short- and long-term operating plans. 23andMe
provides Adjusted EBITDA because 23andMe believes it is frequently
used by analysts, investors and other interested parties to
evaluate companies in its industry and it facilitates comparisons
on a consistent basis across reporting periods. Further, 23andMe
believes it is helpful in highlighting trends in its operating
results because it excludes items that are not indicative of
23andMe’s core operating performance. In particular, 23andMe
believes that the exclusion of the items eliminated in calculating
Adjusted EBITDA provides useful measures for period-to-period
comparisons of 23andMe’s business. Accordingly, 23andMe believes
that Adjusted EBITDA provides useful information in understanding
and evaluating operating results in the same manner as 23andMe’s
management and board of directors.
In evaluating Adjusted EBITDA, you should be aware that in the
future 23andMe will incur expenses similar to the adjustments in
this presentation. 23andMe’s presentation of Adjusted EBITDA should
not be construed as an inference that future results will be
unaffected by these expenses or any unusual or non-recurring items.
Adjusted EBITDA should not be considered in isolation of, or as an
alternative to, measures prepared in accordance with GAAP. Other
companies, including companies in the same industry, may calculate
similarly-titled non-GAAP financial measures differently or may use
other measures to evaluate their performance, all of which could
reduce the usefulness of Adjusted EBITDA as a tool for comparison.
There are a number of limitations related to the use of these
non-GAAP financial measures rather than net loss, which is the most
directly comparable financial measure calculated in accordance with
GAAP. Some of the limitations of Adjusted EBITDA include (i)
Adjusted EBITDA does not properly reflect capital commitments to be
paid in the future, and (ii) although depreciation and amortization
are non-cash charges, the underlying assets may need to be replaced
and Adjusted EBITDA does not reflect these capital expenditures.
When evaluating 23andMe’s performance, you should consider Adjusted
EBITDA alongside other financial performance measures, including
net loss and other GAAP results. Adjusted EBITDA is our best proxy
for cash burn.
ContactsInvestors: investors@23andMe.comMedia:
press@23andMe.com
|
23andMe Holding Co.Condensed Consolidated
Statements of Operations and Comprehensive Loss(In
thousands, except share and per share
data)(Unaudited) |
|
|
Three Months Ended September 30, |
|
Six Months Ended September 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
Service |
$ |
38,514 |
|
|
$ |
42,766 |
|
|
$ |
73,193 |
|
|
$ |
96,026 |
|
Product |
|
5,557 |
|
|
|
7,233 |
|
|
|
11,292 |
|
|
|
14,837 |
|
Total revenue |
|
44,071 |
|
|
|
49,999 |
|
|
|
84,485 |
|
|
|
110,863 |
|
Cost of revenue: |
|
|
|
|
|
|
|
Service |
|
18,801 |
|
|
|
25,227 |
|
|
|
36,050 |
|
|
|
52,172 |
|
Product |
|
2,863 |
|
|
|
3,043 |
|
|
|
5,514 |
|
|
|
6,281 |
|
Total cost of revenue |
|
21,664 |
|
|
|
28,270 |
|
|
|
41,564 |
|
|
|
58,453 |
|
Gross profit |
|
22,407 |
|
|
|
21,729 |
|
|
|
42,921 |
|
|
|
52,410 |
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
|
41,041 |
|
|
|
54,588 |
|
|
|
85,678 |
|
|
|
116,917 |
|
Sales and marketing |
|
16,874 |
|
|
|
18,328 |
|
|
|
32,346 |
|
|
|
40,986 |
|
General and administrative |
|
23,418 |
|
|
|
25,290 |
|
|
|
55,778 |
|
|
|
76,030 |
|
Restructuring and other charges |
|
2,242 |
|
|
|
2,654 |
|
|
|
2,242 |
|
|
|
6,871 |
|
Total operating expenses |
|
83,575 |
|
|
|
100,860 |
|
|
|
176,044 |
|
|
|
240,804 |
|
Loss from operations |
|
(61,168 |
) |
|
|
(79,131 |
) |
|
|
(133,123 |
) |
|
|
(188,394 |
) |
Other income (expense): |
|
|
|
|
|
|
|
Interest income, net |
|
2,009 |
|
|
|
3,752 |
|
|
|
4,583 |
|
|
|
8,059 |
|
Other income (expense), net |
|
15 |
|
|
|
145 |
|
|
|
(4 |
) |
|
|
477 |
|
Loss before income taxes |
|
(59,144 |
) |
|
|
(75,234 |
) |
|
|
(128,544 |
) |
|
|
(179,858 |
) |
Provision for (benefit from) income taxes |
|
(41 |
) |
|
|
36 |
|
|
|
(41 |
) |
|
|
36 |
|
Net loss |
|
(59,103 |
) |
|
|
(75,270 |
) |
|
|
(128,503 |
) |
|
|
(179,894 |
) |
Other comprehensive loss, net of tax |
|
— |
|
|
|
954 |
|
|
|
— |
|
|
|
620 |
|
Total comprehensive loss |
$ |
(59,103 |
) |
|
$ |
(74,316 |
) |
|
$ |
(128,503 |
) |
|
$ |
(179,274 |
) |
Net loss per share of Class A and Class B common stock attributable
to common stockholders (1): |
|
|
|
|
|
|
|
Basic and diluted (1) |
$ |
(2.32 |
) |
|
$ |
(3.17 |
) |
|
$ |
(5.11 |
) |
|
$ |
(7.68 |
) |
Weighted-average shares used to compute net loss per share
(1): |
|
|
|
|
|
|
|
Basic and diluted (1) |
|
25,519,658 |
|
|
|
23,742,914 |
|
|
|
25,151,988 |
|
|
|
23,429,600 |
|
|
|
(1) |
|
Amounts have been adjusted to reflect the reverse stock split that
became effective on October 16, 2024. |
|
23andMe Holding Co.Condensed Consolidated
Balance Sheets(In thousands, except share and per
share amounts)(Unaudited) |
|
|
September 30, 2024 |
|
March 31, 2024 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
126,601 |
|
|
$ |
216,488 |
|
Restricted cash |
|
1,499 |
|
|
|
1,399 |
|
Accounts receivable, net |
|
446 |
|
|
|
3,324 |
|
Inventories |
|
14,846 |
|
|
|
12,465 |
|
Deferred cost of revenue |
|
5,742 |
|
|
|
4,792 |
|
Prepaid expenses and other current assets |
|
39,650 |
|
|
|
16,841 |
|
Total current assets |
|
188,784 |
|
|
|
255,309 |
|
Property and equipment, net |
|
24,814 |
|
|
|
28,351 |
|
Operating lease right-of-use assets |
|
45,104 |
|
|
|
48,894 |
|
Restricted cash, noncurrent |
|
8,974 |
|
|
|
6,974 |
|
Internal-use software, net |
|
20,479 |
|
|
|
20,516 |
|
Intangible assets, net |
|
29,295 |
|
|
|
33,255 |
|
Other assets |
|
1,486 |
|
|
|
1,868 |
|
Total assets |
$ |
318,936 |
|
|
$ |
395,167 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
6,486 |
|
|
$ |
11,571 |
|
Accrued expenses and other current liabilities |
|
67,328 |
|
|
|
42,263 |
|
Deferred revenue |
|
69,751 |
|
|
|
64,827 |
|
Operating lease liabilities |
|
9,266 |
|
|
|
8,670 |
|
Total current liabilities |
|
152,831 |
|
|
|
127,331 |
|
Deferred revenue, noncurrent |
|
— |
|
|
|
10,000 |
|
Operating lease liabilities, noncurrent |
|
62,422 |
|
|
|
67,845 |
|
Other liabilities |
|
1,754 |
|
|
|
1,471 |
|
Total liabilities |
|
217,007 |
|
|
|
206,647 |
|
Stockholders’ equity |
|
|
|
Common stock, par value $0.0001 - Class A shares, 1,140,000,000
shares authorized, 17,514,204 and 16,169,741 shares issued and
outstanding as of September 30, 2024 and March 31, 2024,
respectively; Class B shares, 350,000,000 shares authorized,
8,322,160 and 8,336,229 shares issued and outstanding as of
September 30, 2024 and March 31, 2024, respectively
(1) |
|
3 |
|
|
|
2 |
|
Additional paid-in capital (1) |
|
2,403,517 |
|
|
|
2,361,606 |
|
Accumulated deficit |
|
(2,301,591 |
) |
|
|
(2,173,088 |
) |
Total stockholders’ equity |
|
101,929 |
|
|
|
188,520 |
|
Total liabilities and stockholders’ equity |
$ |
318,936 |
|
|
$ |
395,167 |
|
|
|
(1) |
|
Amounts have been adjusted to reflect the reverse stock split that
became effective on October 16, 2024. |
|
23andMe Holding Co.Condensed Consolidated
Statements of Cash Flows(In
thousands)(Unaudited) |
|
|
Six Months Ended September 30, |
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
Net loss |
$ |
(128,503 |
) |
|
$ |
(179,894 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
Depreciation and amortization |
|
7,948 |
|
|
|
13,714 |
|
Amortization and impairment of internal-use software |
|
4,586 |
|
|
|
2,514 |
|
Stock-based compensation expense |
|
41,063 |
|
|
|
74,840 |
|
Gain on disposal of property and equipment |
|
(55 |
) |
|
|
(5 |
) |
Loss on disposition of Lemonaid Health Limited |
|
— |
|
|
|
2,026 |
|
Other operating activities |
|
— |
|
|
|
(504 |
) |
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable, net |
|
2,878 |
|
|
|
396 |
|
Inventories |
|
(2,381 |
) |
|
|
(4,733 |
) |
Deferred cost of revenue |
|
(950 |
) |
|
|
(406 |
) |
Prepaid expenses and other current assets |
|
(174 |
) |
|
|
(2,433 |
) |
Operating lease right-of-use assets |
|
3,790 |
|
|
|
3,529 |
|
Other assets |
|
381 |
|
|
|
664 |
|
Accounts payable |
|
(5,063 |
) |
|
|
(3,951 |
) |
Accrued expenses and other current liabilities |
|
1,899 |
|
|
|
(5,674 |
) |
Deferred revenue |
|
(5,076 |
) |
|
|
(22,237 |
) |
Operating lease liabilities |
|
(4,826 |
) |
|
|
(4,255 |
) |
Other liabilities |
|
283 |
|
|
|
(65 |
) |
Net cash used in operating activities |
|
(84,200 |
) |
|
|
(126,474 |
) |
Cash flows from investing activities: |
|
|
|
Purchases of property and equipment |
|
(566 |
) |
|
|
(715 |
) |
Proceeds from sale of property and equipment |
|
159 |
|
|
|
5 |
|
Capitalized internal-use software costs |
|
(3,449 |
) |
|
|
(4,758 |
) |
Net cash used in investing activities |
|
(3,856 |
) |
|
|
(5,468 |
) |
Cash flows from financing activities: |
|
|
|
Proceeds from exercise of stock options |
|
58 |
|
|
|
473 |
|
Proceeds from issuance of common stock under employee stock
purchase plan |
|
331 |
|
|
|
1,411 |
|
Payments of deferred offering costs |
|
(2 |
) |
|
|
(263 |
) |
Payments for taxes related to net share settlement of equity
awards |
|
(118 |
) |
|
|
(142 |
) |
Net cash provided by financing activities |
|
269 |
|
|
|
1,479 |
|
Net decrease in cash, cash equivalents and restricted cash |
|
(87,787 |
) |
|
|
(130,463 |
) |
Cash, cash equivalents and restricted cash—beginning of period |
|
224,861 |
|
|
|
395,222 |
|
Cash, cash equivalents and restricted cash—end of period |
$ |
137,074 |
|
|
$ |
264,759 |
|
Reconciliation of cash, cash equivalents, and restricted
cash within the condensed consolidated balance sheets to the
amounts shown in the condensed consolidated statements of cash
flows above: |
|
|
|
Cash and cash equivalents |
$ |
126,601 |
|
|
$ |
256,386 |
|
Restricted cash, current |
|
1,499 |
|
|
|
1,399 |
|
Restricted cash, noncurrent |
|
8,974 |
|
|
|
6,974 |
|
Total cash, cash equivalents and restricted cash |
$ |
137,074 |
|
|
$ |
264,759 |
|
|
|
23andMe Holding Co.Total Company and
Segment Information and Reconciliation of Non-GAAP Financial
Measures(In
thousands)(Unaudited) |
|
The Company's
revenue and Adjusted EBITDA by segment and for the total Company is
as follows: |
|
|
Three Months Ended September 30, |
|
Six Months Ended September 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Segment Revenue: (1) |
|
|
|
|
|
|
|
Consumer and Research Services |
$ |
44,071 |
|
|
$ |
49,999 |
|
|
$ |
84,485 |
|
|
$ |
110,863 |
|
Total revenue |
$ |
44,071 |
|
|
$ |
49,999 |
|
|
$ |
84,485 |
|
|
$ |
110,863 |
|
Segment Adjusted EBITDA: |
|
|
|
|
|
|
|
Consumer and Research Services Adjusted EBITDA |
$ |
(8,633 |
) |
|
$ |
(6,673 |
) |
|
$ |
(17,474 |
) |
|
$ |
(12,275 |
) |
Therapeutics Adjusted EBITDA |
|
(11,975 |
) |
|
|
(26,224 |
) |
|
|
(24,392 |
) |
|
|
(57,363 |
) |
Unallocated Corporate (2) |
|
(12,804 |
) |
|
|
(12,156 |
) |
|
|
(26,708 |
) |
|
|
(25,215 |
) |
Total Adjusted EBITDA |
$ |
(33,412 |
) |
|
$ |
(45,053 |
) |
|
$ |
(68,574 |
) |
|
$ |
(94,853 |
) |
Reconciliation of net loss to Adjusted
EBITDA: |
|
|
|
|
|
|
|
Net loss |
$ |
(59,103 |
) |
|
$ |
(75,270 |
) |
|
$ |
(128,503 |
) |
|
$ |
(179,894 |
) |
Adjustments: |
|
|
|
|
|
|
|
Interest income, net |
|
(2,009 |
) |
|
|
(3,752 |
) |
|
|
(4,583 |
) |
|
|
(8,059 |
) |
Other (income) expense, net |
|
(15 |
) |
|
|
(145 |
) |
|
|
4 |
|
|
|
(477 |
) |
Provision for (benefit from) income taxes |
|
(41 |
) |
|
|
36 |
|
|
|
(41 |
) |
|
|
36 |
|
Depreciation and amortization |
|
4,972 |
|
|
|
4,474 |
|
|
|
8,983 |
|
|
|
8,951 |
|
Amortization of acquired intangible assets |
|
1,775 |
|
|
|
3,638 |
|
|
|
3,551 |
|
|
|
7,277 |
|
Impairment of acquired intangible assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Stock-based compensation expense |
|
19,486 |
|
|
|
23,741 |
|
|
|
41,063 |
|
|
|
74,840 |
|
Loss on disposition of Lemonaid Health Limited and
transaction-related costs |
|
— |
|
|
|
2,127 |
|
|
|
— |
|
|
|
2,375 |
|
Litigation settlement cost |
|
— |
|
|
|
98 |
|
|
|
— |
|
|
|
98 |
|
Cyber security incident expenses, net of probable insurance
recoveries |
|
1,523 |
|
|
|
— |
|
|
|
10,952 |
|
|
|
— |
|
Total Adjusted EBITDA |
$ |
(33,412 |
) |
|
$ |
(45,053 |
) |
|
$ |
(68,574 |
) |
|
$ |
(94,853 |
) |
|
|
(1) |
|
There was no Therapeutics revenue for the three and six months
ended September 30, 2024 and 2023. |
|
(2) |
|
Certain department expenses such
as Finance, Legal, Regulatory and Supplier Quality, Corporate
Communications, Corporate Development, and CEO Office are not
reported as part of the reporting segments as reviewed by the CODM.
These amounts are included in Unallocated Corporate. |
23andMe (NASDAQ:ME)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
Von Dez 2023 bis Dez 2024